1-2 of 2
Siu-Long Yao, MD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Phase 1 Trial of Vodobatinib, a Novel Oral BCR-ABL1 Tyrosine Kinase Inhibitor (TKI): Activity in CML Chronic Phase Patients Failing TKI Therapies Including Ponatinib

Jorge E. Cortes, MD, Tapan Saikia, MD, Dong-Wook Kim, MD, Yesid Alvarado, MD, Franck E Nicolini, MDPhD, Navin Khattry, MD DM, Krishnakumar Rathnam, MD DM, Jane Apperley, FRCP, FRCPath, MB, Michael W. Deininger, MD PhD, Hugues de Lavallade, MD PhD, Aude Charbonnier, MD PhD, Nikki Granacher, MD, Carlo Gambacorti-Passerini, MD, Alessandro Lucchesi, MD, Michael J. Mauro, MD, Gregor Verhoef, MD PhD, Peter Vandenberghe, MD, Andrew R. Whiteley, MD, Shashikant Apte, MD FRCPA, Siu-Long Yao, MD, Mudgal Kothekar, MD, Jayasree Sreenivasan, MSc, Bimba HV, MD, Geetanjali Chimote, MD PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 51–52.
https://doi.org/10.1182/blood-2020-139847
Published: 2020
Journal Articles

Phase 1 Trial of K0706, a Novel Oral BCR-ABL1 Tyrosine Kinase Inhibitor (TKI): In Patients with Chronic Myelogenous Leukemia (CML) and Phildelphia Positive Acute Lymphoblastic Leukemia (Ph+ ALL) Failing ≥ 3 Prior TKI Therapies: Initial Safety and Efficacy

Jorge E. Cortes, MD, Dong-Wook Kim, Franck E Nicolini, MD PhD, Tapan Saikia, MD, Aude Charbonnier, Jane F. Apperley, MD FRCP, FRCPath, MB, Krishna Rathnam, Michael W. Deininger, Hugues De Lavallade, Navin Khattry, MD DM MDcal Oncology, Andrew Whiteley, MD, Michael J. Mauro, MD, Gregor Verhoef, MD PhD, Carlo Gambacorti-Passerini, MD, Alessandro Lucchesi, MD, Shashikant Apte, MD FRCPA, Granacher Nikki, Siu-Long Yao, MD, Mudgal Kothekar, MD, Jayasree Sreenivasan, Msc, Bimba HV, MD, Geetanjali Chimote, MBBS, PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 4158.
https://doi.org/10.1182/blood-2019-129751
Published: 2019